Cargando…

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?

PURPOSE OF REVIEW: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pham, James P., Joshua, Anthony M., da Silva, Ines P., Dummer, Reinhard, Goldinger, Simone M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164011/ https://www.ncbi.nlm.nih.gov/pubmed/36988735 http://dx.doi.org/10.1007/s11912-023-01385-6

Ejemplares similares

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
por: Cheng, Phil F, et al.
Publicado: (2015)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
por: Kraehenbuehl, Lukas, et al.
Publicado: (2023)

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
por: Mangana, Joanna, et al.
Publicado: (2017)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014)

Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?
por: Guadagni, Stefano, et al.
Publicado: (2017)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
por: Goldinger, Simone M, et al.
Publicado: (2015)

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients
por: Goldinger, Simone M, et al.
Publicado: (2012)

Chemotherapy in NEN: still has a role?
por: Espinosa-Olarte, Paula, et al.
Publicado: (2021)

RASopathic Skin Eruptions during Vemurafenib Therapy
por: Rinderknecht, Jeannine D., et al.
Publicado: (2013)

Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
por: Rinderknecht, Jeannine D., et al.
Publicado: (2013)

Staging of cutaneous melanoma
por: Mohr, P., et al.
Publicado: (2009)

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

What Is New in Cutaneous T Cell Lymphoma?
por: Morgenroth, Sarah, et al.
Publicado: (2023)

Correction to: Chemotherapy in NEN: still has a role?
por: Espinosa-Olarte, Paula, et al.
Publicado: (2022)

Selenium for the Prevention of Cutaneous Melanoma
por: Cassidy, Pamela B., et al.
Publicado: (2013)

Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma
por: Lang, Claudia C. V., et al.
Publicado: (2020)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

Recent Progress in the Diagnosis and Treatment of Melanoma and Other Skin Cancers
por: Pawlik, Laura, et al.
Publicado: (2023)

Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review
por: Simon, Aurélien, et al.
Publicado: (2017)

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
por: Dummer, Reinhard, et al.
Publicado: (2023)

A new B-Raf inhibitor combo for advanced melanoma
por: Barysch, Marjam-Jeanette, et al.
Publicado: (2018)

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
por: Guendisch, Ulf, et al.
Publicado: (2022)

Comprehensive analysis of cutaneous and uveal melanoma liver metastases
por: Hoefsmit, Esmee P, et al.
Publicado: (2020)

Adult-onset Still's disease with atypical cutaneous manifestations
por: Narváez Garcia, Francisco Javier, et al.
Publicado: (2017)

Cutaneous melanoma
por: Négrier, S, et al.
Publicado: (2001)

Expression and functional role of CRIPTO-1 in cutaneous melanoma
por: De Luca, A, et al.
Publicado: (2011)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression
por: Saltari, Annalisa, et al.
Publicado: (2021)

Cutaneous melanoma in women()
por: Roh, Mi Ryung, et al.
Publicado: (2015)

Cutaneous melanoma in women()()
por: Roh, Mi Ryung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_80ifkkdi3m0a7varu5dq0ml2a4